---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-118476"
form_type: "8-K"
ticker: "CNMD"
cik: "0000816956"
company_name: "CONMED Corp"
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:26:59.768304+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026

## Summary
- Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.
- Exit projected to cause EPS dilution of $0.45–$0.55 in 2026.
- Consolidated gross margin expected to improve by ~80 bps after exit completion.
- CONMED reaffirms full-year 2025 revenue guidance of $1.365B–$1.372B and adjusted EPS of $4.48–$4.53.
- 2026 guidance to be provided on Q4 2025 earnings call.

## SEC filing metadata
- accession: 0001213900-25-118476
- form_type: 8-K
- ticker: CNMD
- cik: 0000816956
- company_name: CONMED Corp
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/816956/000121390025118476/0001213900-25-118476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/816956/000121390025118476/ea0268554-8k_conmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-118476
- JSON: https://secwatch.observer/filing/0001213900-25-118476.json
- Plain text: https://secwatch.observer/filing/0001213900-25-118476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.